Cytostatic Intravesical Instillation in Patients with Superficial Bladder Carcinoma for the Prevention of Recurrent Tumors

1988 ◽  
Vol 14 (3) ◽  
pp. 202-206 ◽  
Author(s):  
H. Huland ◽  
G. Klöppel ◽  
U. Otto ◽  
I. Feddersen ◽  
W. Brachmann ◽  
...  
Keyword(s):  
Bladder Carcinoma ◽  
Intravesical Instillation ◽  
Recurrent Tumors ◽  
Superficial Bladder Carcinoma

scholarly journals Bladder perforation after immediate postoperative intravesical instillation of mitomycin C

2013 ◽  
Vol 4 (1) ◽  
pp. 1 ◽  
Author(s):  
Darwin Lim ◽  
Jonathan I. Izawa ◽  
Paul Middlebrook ◽  
Joseph L. Chin
Keyword(s):  
Intensive Care ◽  
Single Dose ◽  
Mitomycin C ◽  
Male Patient ◽  
Transurethral Resection ◽  
Bladder Carcinoma ◽  
Adjunctive Therapy ◽  
Intravesical Instillation ◽  
Recurrence Rates ◽  
Superficial Bladder Carcinoma

Intravesical chemotherapy after transurethral resection of a bladdertumour (TURBT) has been observed to significantly decreaserecurrence rates compared to TURBT alone. Though immediatepostoperative intravesical treatment with chemotherapeutic agentsafter transurethral resection for superficial bladder carcinoma isgenerally considered a safe and effective adjunctive therapy indecreasing recurrence rates, its instillation is not always completelyinnocuous. Lately, a more serious complication of bladderperforation associated with immediate instillation of intravesicalmitomycin C (MMC) after TURBT was reported. We reportour own experience of a male patient with bladder perforationafter an early instillation of a single dose of MMC. In this case,systemic toxicity occurred which required intensive care aftersurgical repair.

Long-Term Follow-Up of Cytostatic Intravesical Instillation in Patients with Superficial Bladder Carcinoma

1997 ◽  
Vol 31 (2) ◽  
pp. 153-159 ◽  
Author(s):  
Hartwig Schwaibold ◽  
Uwe Pichlmeier ◽  
Hans-Jörg Klingenberger ◽  
Hartwig Huland
Keyword(s):  
Bladder Carcinoma ◽  
Intravesical Instillation ◽  
Superficial Bladder Carcinoma ◽  
Long Term Follow Up

Early and large-dose intravesical instillation of epirubicin to prevent superficial bladder carcinoma recurrence after transurethral resection

2004 ◽  
Vol 94 (3) ◽  
pp. 317-321 ◽  
Author(s):  
Kenji Mitsumori ◽  
Norihiko Tsuchiya ◽  
Tomonori Habuchi ◽  
Zhenhua Li ◽  
Toshiya Akao ◽  
...  
Keyword(s):  
Transurethral Resection ◽  
Large Dose ◽  
Bladder Carcinoma ◽  
Intravesical Instillation ◽  
Superficial Bladder Carcinoma

scholarly journals INTRAVESICAL INSTILLATION OF BACILLUS CALMETTE-GUERIN FOR SUPERFICIAL BLADDER CARCINOMA

1991 ◽  
Vol 82 (2) ◽  
pp. 290-296 ◽  
Author(s):  
Noboru Yabusaki ◽  
Hideki Komatsu ◽  
Kiichirou Tago ◽  
Yutaka Yamada ◽  
Akira Ueno
Keyword(s):  
Bladder Carcinoma ◽  
Intravesical Instillation ◽  
Bacillus Calmette Guerin ◽  
Superficial Bladder Carcinoma

Results at 5 years of intra vesical gemcitabine (G) single agent as adjuvant chemotheray in superficial transitional cell carcinoma (TCC) of the bladder

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. e16087-e16087
Author(s):  
F. Smaili ◽  
A. Bounedjar ◽  
R. Ferhat ◽  
K. Bouzid
Keyword(s):  
Bladder Carcinoma ◽  
Single Agent ◽  
Transitional Cell ◽  
Intravesical Instillation ◽  
Phase Iii ◽  
Intravesical Therapy ◽  
Superficial Bladder Carcinoma ◽  
Carcinoma Of The Bladder ◽  
Muscle Invasion

e16087 Background: Systemic intravenous gemcitabine is usually used in advanced bladder carcinoma, intravesical G is a novel treatment approach for TCC. In this study we evaluate the efficacy of intravesical Gemcitabine in patients (pts) with superficial bladder carcinoma. Methods: From February 2003 to June 2004, 60 pts (57M/3F) were enrolled in the study (M/F = 57/3). The median age was 59,5 years old (24–84). Nine pts had a carcinoma in situ (Cis) and 51 had pT1 lesions. Three weeks after a total transurethral resection (TUR), patients receive intravesical instillation of 2000 mg G every week for 6 weeks, than every month for six months. They received a total of 720 instillations, Follow up was with cystoscopy and urine cytology every six months. Results: At a median follow-up time 60 months, all patients were evaluable for tumor response: 23(38, 3%) patient had a persistant complete remission after treatment, 26 patients (43,3%) had a superficial relapse of TCC, six patients (10%) had progressive disease: four with muscle invasion and two with distant metastasis. Conclusions: Intravesical therapy with gemcitabine is active and well tolerated treatment in patients with superficial TCC carcinoma of the bladder. A phase III trial comparing GEM with intravesical BCG or MMC is warranted No significant financial relationships to disclose.

Thin-Section CT with Air Insufflation Technique for Bladder Carcinoma: CT Findings of Superficial Bladder Carcinoma

1994 ◽  
Vol 30 (2) ◽  
pp. 347
Author(s):  
Mi Hye Kim ◽  
Kyung Sub Shinn ◽  
Hyun Kim ◽  
Ha Hun Song ◽  
Si Won Kang ◽  
...  
Keyword(s):  
Thin Section ◽  
Bladder Carcinoma ◽  
Ct Findings ◽  
Superficial Bladder Carcinoma ◽  
Air Insufflation
Sign in / Sign up

Export Citation Format

Share Document